Roche had options to buy back the compounds, but decided against doing so in May 2011, after Evotec terminated a Phase II proof-of-concept trial of lead product EVT 101 in treatment-resistant depression because of difficulties in recruiting patients. (See BioWorld International, May 25, 2011.) That decision cost Evotec $65 million due if Roche had exercised the right to take EVT 101 back in-house, plus a further $225 million in development and commercial milestones if the product had made it to

Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International

43 percent is a good signal," Olav Hellebø, CEO of Oslo, Norway-based Clavis told BioWorld International

Andy Burrows, director of investor relations at BTG, told BioWorld International that analysts are predicting "at least a $500 million increase in sales" as a result of the label extensions in the U.S

The tax breaks on offer would attract money from a swath of midrange earners at a time when low interest rates mean returns on traditional savings and investment instruments have hit rock bottom, the BIA said. (See BioWorld International, Sept. 5, 2012.) Stephen Whitehead, chief executive of the Association of the British Pharmaceutical Industry, echoed Bates' assessment, saying a lot more needs to be done to maintain the UK's standing as an attractive place for pharma companies to operate

The decrease associated with tozadenant was "clinically relevant and statistically highly significant," Biotie CEO Timo Veromaa told BioWorld International

Life sciences is what has provided most of the returns at Sofinnova over a long period of time, across all of the funds," managing partner, Antoine Papiernik, told BioWorld International

Panos Deloukas, senior group leader in the department of human genetics at the Wellcome Trust Sanger Institute, told BioWorld International: "We have found new genetic risk factors for CAD

That resulted in last year's ruling, which for some sounded the death knell for human ESC research in Europe. (See BioWorld Today, Oct. 19, 2011.) "People were really jumping to all sorts of conclusions after the CJEU decision was given," Nick Bassil, patent attorney at Kilburn & Strode in London, told BioWorld International...They have effectively acknowledged that there are technologies that you can use to get embryonic stem cells that don't result in the destruction of an embryo," Paul Chapman

We produce the final batch in our own GMP facility," Erytech CEO Pierre-Olivier Goineau told BioWorld International

Companies are facing up to two dimensions of momentum," Julian Remnant, R&D advisory partner at the consultant firm Deloitte, and co-author of the study, told BioWorld International

They have put in €100 million to buy the asset and complete the Phase III trial of Ularitide," he told BioWorld International

We don't have them prioritized," Armstrong told BioWorld International...We've worked to get a portfolio of programs together that target very distinct mechanisms of action in Alzheimer's disease," Bulthuis told BioWorld International

We believe it can be much broader than that," Eporgen's president, Konstantinos Efthymiopoulos, told BioWorld International

Canterbury, UK $27 Ziarco received $27M through a Series A round led by Biotechnology Venture Fund LP and including Pfizer Venture Investments 11/5/12 Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International

The up-front is not as important as the 10 percent royalty rate, which is a significant achievement for us," Mikael Bronnegard, CEO of NeuroVive, told BioWorld International

It is a major beneficiary of a recent increase in Sweden's science budget. (See BioWorld International, Sep. 12, 2012.) At SEK40 million (US$6 million) per year for the next four years, SciLifeLab's funding for drug development is, Uhlen said, "a drop in the ocean" compared with big pharma's R&D spend, although the available cash should leverage additional external funding...It's a wonderful opportunity," CEO Anders Dahlstrand told BioWorld International

We've trained Lactococcus lactis bacteria to introduce lanthionine rings into any peptide that we're interested in," CEO Bart Wuurman told BioWorld International...We haven't allocated a fixed amount that we want to invest," MorphoSys' chief financial officer, Jens Holstein, told BioWorld International

We want funds to get the two products to the end of Phase I, so a reasonable amount is needed for that," Keith Martin, CEO, told BioWorld International